1-4 of 4
Andrew A Guirguis
Close
Sort by
Journal Articles

A Rare Cell State Underpins Diverse Mechanisms of Adaptive Resistance to CAR T-Cell Therapy in B-Cell Acute Lymphoblastic Leukemia

James A Kuzich, Laure Talarmain, Dane Vassiliadis, Andrew A Guirguis, Jack D Chan, Paul A Beavis, Phillip K Darcy, Ashley P Ng, Mark A Dawson
Journal: Blood
Blood (2023) 142 (Supplement 1): 887.
https://doi.org/10.1182/blood-2023-191111
Published: 2023
Journal Articles

Using an in-Vivo Degron-Based Approach to Interrogate Dependencies of Serially Acquired Mutations - Including DNMT3a-R882 and NPM1c - in Acute Myeloid Leukemia

Andrew A Guirguis, MD PhD, Alexander Tepper, Max Jan, MD PhD, Quinlan Sievers, MD PhD, Benjamin L. Ebert, MDPhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 12–13.
https://doi.org/10.1182/blood-2020-142566
Published: 2020
Journal Articles

Exploiting the Zinc Finger Degrome Targeted By Lenalidomide to Engineer Reversible Off-Switch Degradable Chimeric Antigen Receptors

Max Jan, MD PhD, Ana Castano, MD, Amanda Walker, BA, Andrew A Guirguis, MD PhD, Jessica A Gasser, PhD, Amanda A Bouffard, Mikolaj Slabicki, PhD, Alexander Tepper, Daniel E Grinshpun, Taeyoon Kyung, PhD, Quinlan Sievers, MD PhD, Michael E Birnbaum, PhD, Marcela V Maus, MD PhD, Benjamin L. Ebert, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 866.
https://doi.org/10.1182/blood-2019-124210
Published: 2019
Journal Articles

Crbn I391V is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice

Emma C. Fink, Marie McConkey, Dylan N. Adams, Saurav D. Haldar, James A. Kennedy, Andrew A. Guirguis, Namrata D. Udeshi, D. R. Mani, Michelle Chen, Brian Liddicoat, Tanya Svinkina, Andrew T. Nguyen, Steven A. Carr, Benjamin L. Ebert
Journal: Blood
Blood (2018) 132 (14): 1535–1544.
https://doi.org/10.1182/blood-2018-05-852798
Published: 2018
Includes: Supplemental data